150 related articles for article (PubMed ID: 38586301)
1. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F; Sebastian M; Brueckl WM; Hummel HD; Jaeschke B; Kern J; Wesseler C; Jänicke M; Fleitz A; Zacharias S; Hipper A; Groth A; Weichert W; Dörfel S; Petersen V; Schröder J; Wilke J; Eberhardt WEE; Thomas M;
JTO Clin Res Rep; 2024 Apr; 5(4):100626. PubMed ID: 38586301
[TBL] [Abstract][Full Text] [Related]
2. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers.
Parikh RB; Min EJ; Wileyto EP; Riaz F; Gross CP; Cohen RB; Hubbard RA; Long Q; Mamtani R
JAMA Oncol; 2021 Dec; 7(12):1843-1850. PubMed ID: 34734979
[TBL] [Abstract][Full Text] [Related]
6. Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab.
Jemielita T; Li XN; Burke T; Liaw KL; Zhou W; Chen C
JCO Clin Cancer Inform; 2021 Aug; 5():849-858. PubMed ID: 34415774
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D; Morimoto T; Tamiya M; Hata A; Matsumoto H; Nakamura A; Yokoyama T; Taniguchi Y; Uchida J; Sato Y; Yokoi T; Tanaka H; Furuya N; Masuda T; Sakata Y; Miyauchi E; Hara S; Saito G; Miura S; Kanazu M; Yamamoto N; Akamatsu H
JAMA Netw Open; 2023 Feb; 6(2):e230698. PubMed ID: 36826813
[TBL] [Abstract][Full Text] [Related]
8. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.
Velcheti V; Hu X; Yang L; Pietanza MC; Burke T
Front Oncol; 2022; 12():834761. PubMed ID: 35402266
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Heng DY; Choueiri TK; Rini BI; Lee J; Yuasa T; Pal SK; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie M; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Agarwal N; Kollmannsberger C; North S; Wood LA
Ann Oncol; 2014 Jan; 25(1):149-54. PubMed ID: 24356626
[TBL] [Abstract][Full Text] [Related]
12. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
[TBL] [Abstract][Full Text] [Related]
13. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.
Goto Y; Tamura A; Matsumoto H; Isobe K; Ozaki T; Santorelli ML; Taniguchi K; Kamitani T; Irisawa M; Kanda K; Abe M; Burke T; Nokihara H
JTO Clin Res Rep; 2022 Sep; 3(9):100397. PubMed ID: 36065450
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Target Oncol; 2022 Jul; 17(4):475-482. PubMed ID: 35789472
[TBL] [Abstract][Full Text] [Related]
18. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
19. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.
Karim S; Xu Y; Kong S; Abdel-Rahman O; Quan ML; Cheung WY
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e160-e166. PubMed ID: 31133363
[TBL] [Abstract][Full Text] [Related]
20. Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Aldaoud A; Hutzschenreuter U; Klausmann M; Dille S; Wetzel N; Jänicke M; Marschner N;
Ann Hematol; 2018 Dec; 97(12):2437-2445. PubMed ID: 30069704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
